Sun Life U.S. teamed up with several other Florida-based companies to provide needed assistance in areas impacted by the recent storms.
Two major hurricanes swept through the southeastern coastal states in September and October of 2024. As a result, many communities found themselves temporarily cut off from regular services, including access to care and medication.
Sun Life announced a partnership with Amaze Health, AYG Wellness, and Virtual Wellness Care in order to provide care to people living in areas impacted by the storms.1 This includes expanding access to services and leveraging relationships with various health care providers in the surrounding areas.
In a press release, Sun Life U.S.’ president of health and risk solutions Jen Collier said, “The recent hurricanes caused unbelievable destruction to many lives and infrastructure, including health care. It is clear the recovery will take some time. With facilities damaged, shortages in medical supplies and staffing, and evacuations, access to healthcare has become a challenge. To address this gap, we are collaborating with healthcare partners to offer convenient services by phone or designated website, ensuring members get the care they need during this stressful and uncertain time."
Amaze Health’s CEO David Silverstein added, “In times of crisis, accessing local medical resources can be difficult. The doctor's office may be closed, the dentist's office flooded, and the local emergency room overloaded. Our national medical practice makes resources from all over the country available at the touch of a button."
In the same press release, Virtual Wellness Care CEO Todd Wesson said, “We are happy to be working with Sun Life's Health Navigator and AYG Wellness on the recent disaster relief efforts. The Virtual Wellness High technology works extremely well with Health Navigator's high-touch philosophy. This collaboration will make access to healthcare easier and more convenient to those affected by the recent hurricanes."
"At AYG Wellness, we believe that everyone deserves access to quality care, especially in times of crisis," said Andrea Millsap-Bolden, CEO of AYG Wellness. "Our partnership is about bringing much-needed support to communities impacted by the hurricanes. By leveraging innovative technology and personalized service, we are committed to ensuring that individuals and families can access the care and resources they need to begin their journey toward recovery. Together, we're offering more than just aid—we're providing a pathway to hope, healing, and a healthier future."
Sun Life also recently announced a $50,000 donation to the Volunteer Florida Foundation’s Disaster Fund, Rebuilding Tampa Bay, and Feed Tampa Bay organizations.2
In a press release, Sun Life U.S. president Dan Fishbein, MD, said, “Our thoughts are with those in Florida, many facing the impacts of two major hurricanes. With such devastation, we hope that support from Sun Life and other public and private donations will help people who are struggling start to recover. We are also making every effort to provide the necessary support to our clients, members and Sun Life employees who live in Florida."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.